His pioneering work, in particular in slow-release medicines, provides helped thousands of people throughout the world. Related StoriesResearchers develop 3D bone marrow that produces functional human platelets ex vivoUnderstanding the causes of sudden loss of life in epilepsy: an interview with Professor Sanjay SisodiyaRice and Penn researchers create silicon construct with complex network of bloodstream vesselsLanger pioneered the field of slow-release medications, which provide consistent amounts of a medication over a long period, reducing the amount of pills that a patient has to take.The acquisition of Oculeve provides novel, complementary dry eye development programs to Allergan's current eye care advancement and research programs, including OD-01, a noninvasive nasal neurostimulation device that increases tear creation in patients with dry out attention disease. Oculeve has completed four medical studies of OD-01 to date in more than 200 patients, showing positive protection and efficacy of the device. Allergan plans to conduct two additional pivotal trials prior to FDA submission, which is definitely anticipated in 2016 with potential commercial release in 2017. Chronic dried out eye is an illness that can be caused by advanced age, contact lens wear, certain medications, eye diseases, additional medical conditions or environmental factors.